FDA Sets Up Afrezza Panel To Split Between Type 1 And 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency briefing documents for April 1 meeting suggest greater efficacy concerns in type 1 diabetics, although review of most recent trial in type 2 patients cites “surprisingly modest” treatment effects compared to other drugs. Safety issues for panel consideration include pulmonary function effects and lung cancer.